WHITEHAWK THERAPEUTICS INC
WHWKNASDAQ🏆 #2800 by market capEarnings Nov 5US Equity
$4.67▲ $0.12 (+2.64%)
🌙 After hours$4.67▲ 0.00%Regular close · extended-hours price shown1h—
24h▲ 2.6%
7d▲ 14.3%
14d▲ 27.9%
30d▲ 21.8%
1y▲ 169.9%
🏦Market Cap
$266M
Small Cap
📈Revenue Growth (YoY)
-72.5%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
46
Weak
Trading Snapshot
- Day Range
- $4.65 – $4.76
- 52-Week Range
- $1.57 – $5.50
- Volume
- $1.90B
- Avg Volume
- $2.24B
- Shares Outstanding
- 57.0M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- -4.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.96
- Dividend Yield
- 0.00%
Why Investors Own WHWK
- ✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$7M▼ −0.8% YoY
Gross Margin (TTM)
74.9%▲ +0.8% YoY
Operating Income (TTM)
$2M▼ −0.8% YoY
Free Cash Flow (TTM)
$2M▼ −0.8% YoY
About WHITEHAWK THERAPEUTICS INC
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$5.26
▲ +12.6% Upside
High Target$6.22
Low Target$4.50
Based on 32 analysts
Latest News & Updates
🚀
Reuters·2h ago
WHITEHAWK THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift WHWK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
WHITEHAWK THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.